Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma

Cancer Gene Therapy

Volumn 5, Issue 5, 1998, Pages 292-300

  Nemunaitis, John ^a,b,d   Bohart, Cheryl ^c   Fong, Tim ^c   Meyer, Wally ^a   Edelman, Gerald ^a   Paulson, R Steven ^a,b   Orr, Douglas ^a,b   Jain, Vinay ^a   O'Brien, John ^b   Kuhn, Joseph ^b   Kowal, K Jon ^c   Burkeholder, Susan ^b   Bruce, Janet ^a   Ognoskie, Nadine ^a   Wynne, Dee ^c   Martineau, Darlene ^c   Ando, Dale ^c  

^a Physician Reliance Network   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Clinical Research   (United States)

Author keywords

Autologous tumor cells; Interferon ; Melanoma; Retroviral vector

Indexed keywords

CANCER ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CANCER TRANSPLANTATION; CELL CULTURE; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; INJECTION; MALE; MELANOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PHASE 1 CLINICAL TRIAL; RADIATION EXPOSURE; RETROVIRUS; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEOPLASM; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INJECTIONS; INTERFERON TYPE II; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RETROVIRIDAE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0032152332     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Koh HK. Cutaneous melanoma. N Engl J Med. 1991;325: 171-182.
2. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma. 2nd Ed. Philadelphia: J.B. Lippincott; 1992.
3. Del Prete SA, Maurer LH, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, decarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984;68(11):1403-1405.
4. Sparano JA, Dutcher JP. Interleukin-2 for the treatment of advanced melanoma. Melanoma. 1993;1(4):189-195.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
6. Sosman JA, Weiss GR, Margolin KA, et al. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol 1993;11(8):1496-1505.
7. Rosenberg SA, Lotzke MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889-897.
8. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;316:889-897.
9. Agah R, Malloy B, Sherrod A, et al. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of γ-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res. 1988;48:2245-2248.
10. Maekawa R, Kitagawa T, Hojo K, et al. Differential efficacies of recombinant murine interferon-γ and recombinant human interleukin-2 against EL4-bearing mice. J Interferon Res. 1988;8:241-249.
11. Silagi S, Dutkowski R, Schaefer A. Eradication of mouse melanoma by combining treatment with recombinant human interleukin-2 and recombinant murine interferon-γ. Int J Cancer. 1988;41:315-322.
12. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol. 1989;143:1210-1214.
13. Wallach D, Fellous M, Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature. 1982;299:833-836.
14. Culver KW. Clinical applications of gene therapy for cancer. Clin Chem. 1994;40(4):510-512.
15. Schmidt-Wolf GD, Schmidt-Wolf IG. Cytokines and gene therapy. Immunol Today. 1995;16:173-175.
16. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994;15(2):48-51.
17. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
18. Walsh P, Dorner A, Duke RC, et al. Macrophage colonystimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst. 1995;87(11):809-816.
19. Rosenthal FM, Cronin K, Bannerji R, et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood. 1994;83(5):1289-1298.
20. Seigler HF, Darrow TL, Abdel-Wahab Z, et al. A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther. 1994;5:761-777.
21. Abdel-Wahab Z, Dar M, Osanto S. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or γ-interferon. Cancer Gene Ther. 1997;4(1):33-41.
22. Lebovitz A, Liu R, Hayes C, et al. A hypo-osmotic medium to desegregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay. Int J Cell Cloning. 1983;1:478-485.
23. Nemunaitis J, Appelbaum F, Lilleby K, et al. Phase I study of recombinant interleukin-1 Beta (rhIL-1J) in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood. 1994;83(12):3473-3479.
24. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndrome and thrombocytopenia. Blood. 1995;85:3066-3076.
25. Qin H, Chatterjee SK. Recombinant vaccine expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther. 1996;3(3):163-167.
26. Panelli MC, Wang E, Shen S, et al. Interferon gamma (IFNγ) gene transfer of an EMT6 tumor that is poorly responsive to IFNγ stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II trans-activator and class II MHC. Cancer Immunol Immumother. 1996;42(2):99-107.
27. Berman RM, Suzuki T, Tahara H, et al. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996;157(1):231-238.
28. Lindemann A, Brossart P, Hoffken K, et al. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study. Cancer Immunol Immunother. 1993;37:307-315.
29. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony stimulating factor production by melanoma cells. Cancer Res. 1996;56(9): 2191-2198.
30. Albertini MR, Emler CA, Schell K, et al. Dual expression of human leukocyte antigen molecules, and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. Cancer Gene Ther. 1996;3(3):192-201.
31. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997;15(1):341-349.
32. Abe J, Wakimoto H, Tsunoda R, et al. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-7 by adenovirus-mediated genetic transduction. Biochein Biophys Res Commun. 1996;218(1):164-170.